Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteriaGuido Finazzi, Tiziano Barbui, J. Thiele et al.|Leukemia|2011Cited by 182
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaHeinz Gisslinger, J. Thiele, Georg Jeryczynski et al.|Leukemia|2015Cited by 62
Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaHeinz Gisslinger, J. Thiele, Georg Jeryczynski et al.|Leukemia|2017Cited by 8
group O, and Bombay, a rare FUT1 null phenotype lacking H and AB antigens.Laura Cooling, Fisher R. Interac, Sandra Hoffmann et al.|Unknown|2008Cited by 0
PS1470 EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIAVeronika Buxhofer‐Ausch, Heinz Gisslinger, Michael Steurer et al.|HemaSphere|2019Cited by 0